Clinical Immunology

Clinical immunology: The new immunotherapies

This year’s HOT TOPIC focuses on “Clinical immunology: The new immunotherapies“, for the practising dermatologist.  32 of Europe’s leading immunologists will teach us clinicians what we need to know about allergic, autoimmune and auto-inflammatory diseases, immune-deficiencies, as well as the immunotherapies of infectious and malignant diseases.

Below is a preview of the stimulating topics that will be discovered and covered over the two full days…

Day 1 – Thursday, 14 September

Clinical immunology: Allergic diseases

  • Pathogenesis of sensitisation
  • Type I and type IV allergies
  • Environmental factors and allergy
  • IgE mediated diseases, mast cell dysfunction and their treatment
  • Contact hypersensitivity
  • Atopic dermatitis
  • IL-4/IL-13 antagonists: How do they work?
  • Desensitisation


Clinical immunology: Autoimmune diseases

  • Antibody-mediated autoimmune diseases: Using pemphigus as a model
  • Cell-mediated autoimmune diseases: Using lichen planus as a model
  • Bullous autoimmune diseases: Why do they look different?
  • TNF and TNF antagonist: How do they work?
  • IL-12 antagonists and T-cell based immunosuppression
  • IL-17/IL-23 and their antagonists: How do they work?
  • B-cell based immunosuppression
  • Intravenous immunoglobulins


Day 2 – Friday, 15 September

Clinical immunology: Auto-inflammatory diseases

  • Definition and spectrum of auto-inflammatory diseases
  • Inflammasome: An intracellular sensor of danger
  • IL-1, IL-1 antagonists and fever syndromes
  • IL-1 family and pustular diseases


Clinical immunology: Immunodeficiencies

  • Primary immune-deficiencies relevant to dermatology
  • Immunodeficiencies in HIV infection
  • Risks of small molecule-immuno-suppressants
  • Infections induced by natalizumab, CTLA-4-Ig, B-cell depletion and related drugs


Clinical immunology: Immunotherapy of infectious diseases

  • Beta-defensins in cutaneous infection
  • Modes of adaptive immunity to infection
  • HPV and zoster vaccines: Mode of action and efficacy
  • Live attenuated and inactivated vaccines: Benefits and risks


Clinical immunology: Immunotherapy of malignant diseases

  • Tumour microenvironment
  • New perspectives for anti-cancer vaccines: Personalisation and combination
  • Exploiting antiviral defense for cancer immunotherapy
  • CTLA4 and PD-1/PD-L1 antagonists: Mode of action


The full programme with confirmed speakers is available for viewing here.

Back to top